Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

EDWARD MEZERHANE

Allopathic & Osteopathic Physicians Internal Medicine Sleep Medicine

NPI
1063654218
CMS profile
792210
Location
MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$84,286.40

98 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
JAZZ PHARMACEUTICALS INC. $64,008.25 68
HARMONY BIOSCIENCES LLC $16,281.96 14
Eisai Inc. $3,803.09 10
Fisher & Paykel Healthcare Inc $85.90 2
Medtronic, Inc. $58.98 1
ARBOR PHARMACEUTICALS, INC. $48.22 3

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

EDWARD MEZERHANE

NPI 1063654218 · CMS profile ID 792210

Allopathic & Osteopathic Physicians / Internal Medicine / Sleep Medicine

MIAMI, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1063654218?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
EDWARD MEZERHANE, NPI 1063654218, CMS profile ID 792210. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1063654218?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). EDWARD MEZERHANE, NPI 1063654218, CMS profile ID 792210. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1063654218?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
EDWARD MEZERHANE, NPI 1063654218, CMS profile ID 792210, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–98 of 98 matching records. This page contains 48 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1063654218?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

98 matching records · $84,286.40 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 98 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–98 of 98.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
JAZZ PHARMACEUTICALS INC. $125.0008/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608539 CMS
JAZZ PHARMACEUTICALS INC. $21.4008/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608579 CMS
JAZZ PHARMACEUTICALS INC. $1,125.0008/02/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608743 CMS
JAZZ PHARMACEUTICALS INC. $18.1207/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845550625 CMS
JAZZ PHARMACEUTICALS INC. $113.9607/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845550623 CMS
JAZZ PHARMACEUTICALS INC. $189.2007/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603093 CMS
JAZZ PHARMACEUTICALS INC. $189.2007/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608533 CMS
JAZZ PHARMACEUTICALS INC. $189.2007/22/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608573 CMS
JAZZ PHARMACEUTICALS INC. $2,000.0007/21/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845608421 CMS
ARBOR PHARMACEUTICALS, INC. $15.6406/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830922761 CMS
JAZZ PHARMACEUTICALS INC. $140.0006/28/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607387 CMS
HARMONY BIOSCIENCES LLC $48.6006/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078691 CMS
HARMONY BIOSCIENCES LLC $2,500.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078697 CMS
HARMONY BIOSCIENCES LLC $48.6006/24/2021 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078705 CMS
HARMONY BIOSCIENCES LLC $2,500.0006/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078715 CMS
JAZZ PHARMACEUTICALS INC. $3,150.0006/23/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607389 CMS
JAZZ PHARMACEUTICALS INC. $112.7106/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845607385 CMS
JAZZ PHARMACEUTICALS INC. $60.2606/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845594087 CMS
JAZZ PHARMACEUTICALS INC. $3,150.0006/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845606699 CMS
JAZZ PHARMACEUTICALS INC. $375.0005/18/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602075 CMS
Eisai Inc. $17.5305/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817944389 CMS
HARMONY BIOSCIENCES LLC $47.7005/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078711 CMS
HARMONY BIOSCIENCES LLC $1,440.0005/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853078695 CMS
JAZZ PHARMACEUTICALS INC. $122.0605/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845604753 CMS
JAZZ PHARMACEUTICALS INC. $3,150.0005/05/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845606567 CMS
Eisai Inc. $100.1504/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833760907 CMS
Eisai Inc. $1,500.0004/29/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833778871 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0004/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602279 CMS
JAZZ PHARMACEUTICALS INC. $21.5704/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845578117 CMS
JAZZ PHARMACEUTICALS INC. $122.2904/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845603911 CMS
ARBOR PHARMACEUTICALS, INC. $13.0304/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 830922743 CMS
Medtronic, Inc. $58.9804/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 815692067 CMS
JAZZ PHARMACEUTICALS INC. $450.0004/06/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602269 CMS
Eisai Inc. $300.0004/01/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833774947 CMS
JAZZ PHARMACEUTICALS INC. $18.8604/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845584161 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0003/11/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602261 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0003/05/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602259 CMS
Eisai Inc. $19.1602/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 817849333 CMS
Eisai Inc. $450.0002/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833755419 CMS
JAZZ PHARMACEUTICALS INC. $23.5602/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845581389 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0002/10/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602249 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0002/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845601675 CMS
JAZZ PHARMACEUTICALS INC. $3,000.0002/03/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845601385 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0001/29/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602245 CMS
Eisai Inc. $450.0001/26/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833755379 CMS
JAZZ PHARMACEUTICALS INC. $1,350.0001/22/2021 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845602241 CMS
Eisai Inc. $500.0001/21/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833754743 CMS
Eisai Inc. $450.0001/13/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 833778117 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $64,263.86 114
PY2020 $39,395.34 68
PY2021 $84,286.40 98
PY2022 $51,703.51 83
PY2023 $74,966.38 119
PY2024 $74,923.77 119
PY2025 $147,789.65 227

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $358,524.86 227
PY2024 Principal investigator $603,705.25 215
PY2023 Principal investigator $335,810.26 27
PY2022 Principal investigator $80,402.67 23
PY2021 Principal investigator $7,301.00 3
PY2020 Principal investigator $8,656.00 4

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

227 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Avadel CNS Pharmaceuticals, LLC $60,341.19 12/31/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE LLC
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL, MULTICENTER STUDY OF THE EFFICACY AND SAFETY OF FT218 IN THE TREATMENT OF IDIOPATHIC HYPERSOMNIA (IH) No dispute reported 06/30/2026 1208554193
Principal investigator 1 Alkermes, Inc. $2,704.00 12/23/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614142
Principal investigator 1 Alkermes, Inc. $70.00 12/23/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617811
Principal investigator 1 Alkermes, Inc. $75.20 12/08/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615589
Principal investigator 1 Alkermes, Inc. $71.60 12/08/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616911
Principal investigator 1 Alkermes, Inc. $159.00 12/08/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622932
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.65 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741764
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $0.66 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741766
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $60.20 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741768
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1.92 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741770
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $22.00 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741772
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $30.10 11/24/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741774
Principal investigator 1 Alkermes, Inc. $15.16 11/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616519
Principal investigator 1 Alkermes, Inc. $68.40 11/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616909
Principal investigator 1 Alkermes, Inc. $38.82 11/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625401
Principal investigator 1 Alkermes, Inc. $75.20 11/05/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617969
Principal investigator 1 Alkermes, Inc. $79.50 11/05/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623170
Principal investigator 1 Alkermes, Inc. $35.80 11/05/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625648
Principal investigator 1 LivaNova USA, Inc. $100.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552526
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552531
Principal investigator 1 LivaNova USA, Inc. $767.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552535
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552539
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552543
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552546
Principal investigator 1 LivaNova USA, Inc. $767.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552550
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552555
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552558
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552562
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552566
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552570
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552574
Principal investigator 1 LivaNova USA, Inc. $217.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552578
Principal investigator 1 LivaNova USA, Inc. $217.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552582
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552587
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552592
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552596
Principal investigator 1 LivaNova USA, Inc. $14,791.25 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245552601
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552743
Principal investigator 1 LivaNova USA, Inc. $217.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552749
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552755
Principal investigator 1 LivaNova USA, Inc. $767.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552759
Principal investigator 1 LivaNova USA, Inc. $100.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552765
Principal investigator 1 LivaNova USA, Inc. $1,945.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552768
Principal investigator 1 LivaNova USA, Inc. $840.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552771
Principal investigator 1 LivaNova USA, Inc. $253.75 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552777
Principal investigator 1 LivaNova USA, Inc. $253.75 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552782
Principal investigator 1 LivaNova USA, Inc. $253.75 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552786
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552788
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552791
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552795
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552799
Principal investigator 1 LivaNova USA, Inc. $72.50 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552803
Principal investigator 1 LivaNova USA, Inc. $840.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552807
Principal investigator 1 LivaNova USA, Inc. $840.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552809
Principal investigator 1 LivaNova USA, Inc. $1,945.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552813
Principal investigator 1 LivaNova USA, Inc. $1,945.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552817
Principal investigator 1 LivaNova USA, Inc. $145.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552822
Principal investigator 1 LivaNova USA, Inc. $100.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552826
Principal investigator 1 LivaNova USA, Inc. $100.00 10/31/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552829
Principal investigator 1 Alkermes, Inc. $345.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614571
Principal investigator 1 Alkermes, Inc. $1,500.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614573
Principal investigator 1 Alkermes, Inc. $1,200.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614575
Principal investigator 1 Alkermes, Inc. $1,000.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614577
Principal investigator 1 Alkermes, Inc. $850.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208615033
Principal investigator 1 Alkermes, Inc. $2,000.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617531
Principal investigator 1 Alkermes, Inc. $821.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617973
Principal investigator 1 Alkermes, Inc. $200.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620349
Principal investigator 1 Alkermes, Inc. $6,049.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624524
Principal investigator 1 Alkermes, Inc. $2,342.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625169
Principal investigator 1 Alkermes, Inc. $750.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208625888
Principal investigator 1 Alkermes, Inc. $600.00 10/22/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626050
Principal investigator 1 Alkermes, Inc. $7,893.00 09/25/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614240
Principal investigator 1 Alkermes, Inc. $7,252.00 09/25/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615719
Principal investigator 1 Alkermes, Inc. $2,540.00 09/25/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208616589
Principal investigator 1 Alkermes, Inc. $5,946.00 09/25/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618099
Principal investigator 1 Alkermes, Inc. $71.60 09/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617835
Principal investigator 1 Alkermes, Inc. $131.60 09/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621106
Principal investigator 1 Alkermes, Inc. $172.25 09/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622791
Principal investigator 1 Alkermes, Inc. $51.75 09/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623298
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $200.00 08/21/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741754
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,500.00 08/21/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741756
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $6,000.00 08/21/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741758
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,600.00 08/21/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741760
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $35,828.90 08/21/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741762
Principal investigator 1 Alkermes, Inc. $4,916.00 08/20/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615125
Principal investigator 1 Alkermes, Inc. $4,157.00 08/20/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208617837
Principal investigator 1 Alkermes, Inc. $2,648.00 08/20/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624166
Principal investigator 1 Alkermes, Inc. $70.00 08/13/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618555
Principal investigator 1 Alkermes, Inc. $1,196.53 07/17/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618061
Principal investigator 1 Alkermes, Inc. $1,045.00 07/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623902
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613191
Principal investigator 1 Alkermes, Inc. $16.00 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208613605
Principal investigator 1 Alkermes, Inc. $15.39 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208614871
Principal investigator 1 Alkermes, Inc. $33.32 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616213
Principal investigator 1 Alkermes, Inc. $74.24 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616617
Principal investigator 1 Alkermes, Inc. $25.00 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208616855
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617055
Principal investigator 1 Alkermes, Inc. $1.71 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617409
Principal investigator 1 Alkermes, Inc. $162.05 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617607
Principal investigator 1 Alkermes, Inc. $5.95 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208617663
Principal investigator 1 Alkermes, Inc. $127.40 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618149
Principal investigator 1 Alkermes, Inc. $192.75 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208618859
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619273
Principal investigator 1 Alkermes, Inc. $50.15 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208619339
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208620880
Principal investigator 1 Alkermes, Inc. $29.40 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621490
Principal investigator 1 Alkermes, Inc. $51.55 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208621786
Principal investigator 1 Alkermes, Inc. $27.82 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622007
Principal investigator 1 Alkermes, Inc. $29.96 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208622627
Principal investigator 1 Alkermes, Inc. $167.05 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623564
Principal investigator 1 Alkermes, Inc. $34.35 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208623774
Principal investigator 1 Alkermes, Inc. $1.74 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624150
Principal investigator 1 Alkermes, Inc. $5.25 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208624658
Principal investigator 1 Alkermes, Inc. $12.06 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625037
Principal investigator 1 Alkermes, Inc. $74.80 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625477
Principal investigator 1 Alkermes, Inc. $32.70 06/18/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208625984
Principal investigator 1 Vanda Pharmaceuticals Inc. $2,000.00 06/13/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
EVALUATING THE EFFECTS OF TASIMELTEON VS. PLACEBO IN DELAYED SLEEP-WAKE PHASE DISORDER (DSWPD) No dispute reported 06/30/2026 1232945542
Principal investigator 1 Alkermes, Inc. $16.49 06/08/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620129
Principal investigator 1 Alkermes, Inc. $6.41 06/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622271
Principal investigator 1 Alkermes, Inc. $27.28 06/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208622936
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208613149
Principal investigator 1 Alkermes, Inc. $341.02 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614665
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614885
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614887
Principal investigator 1 Alkermes, Inc. $50.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615463
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208615705
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208618573
Principal investigator 1 Alkermes, Inc. $35.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619511
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620003
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620786
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208621098
Principal investigator 1 Alkermes, Inc. $220.78 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623028
Principal investigator 1 Alkermes, Inc. $18.06 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208623828
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624598
Principal investigator 1 Alkermes, Inc. $135.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208624830
Principal investigator 1 Alkermes, Inc. $20.25 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208625886
Principal investigator 1 Alkermes, Inc. $20.00 06/06/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626764
Principal investigator 1 Alkermes, Inc. $300.00 06/04/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208616489
Principal investigator 1 Alkermes, Inc. $2,000.00 06/04/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620435
Principal investigator 1 Alkermes, Inc. $8,000.00 06/04/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208624284
Principal investigator 1 Alkermes, Inc. $742.31 05/20/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208620874
Principal investigator 1 Alkermes, Inc. $641.10 05/16/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208619019
Principal investigator 1 LivaNova USA, Inc. $3,242.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245552633
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552730
Principal investigator 1 LivaNova USA, Inc. $1,351.25 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552734
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552833
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552837
Principal investigator 1 LivaNova USA, Inc. $1,351.25 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552841
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552845
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552850
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552854
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552858
Principal investigator 1 LivaNova USA, Inc. $67.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552862
Principal investigator 1 LivaNova USA, Inc. $3,242.50 05/16/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245553027
Principal investigator 1 Alkermes, Inc. $1,196.53 05/07/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208626752
Principal investigator 1 LivaNova USA, Inc. $4,001.35 05/06/2025 Covered Recipient Teaching Hospital
Hca Florida Westside Hospital
OSPREY No dispute reported 06/30/2026 1245560595
Principal investigator 1 LivaNova USA, Inc. $5,088.00 05/06/2025 Covered Recipient Teaching Hospital
Hca Florida Westside Hospital
OSPREY No dispute reported 06/30/2026 1245560600
Principal investigator 1 LivaNova USA, Inc. $5,088.00 05/06/2025 Covered Recipient Teaching Hospital
Hca Florida Westside Hospital
OSPREY No dispute reported 06/30/2026 1245560678
Principal investigator 1 Alkermes, Inc. $1,045.00 05/01/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Randomized, Parallel-Group, Double-Blind, Dose-Range-Finding Study to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Idiopathic Hypersomnia (Vibrance 3) No dispute reported 06/30/2026 1208614186
Principal investigator 1 Alkermes, Inc. $259.54 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208613415
Principal investigator 1 Alkermes, Inc. $82.08 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208614963
Principal investigator 1 Alkermes, Inc. $119.36 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208618655
Principal investigator 1 Alkermes, Inc. $77.64 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208620936
Principal investigator 1 Alkermes, Inc. $113.34 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208621784
Principal investigator 1 Alkermes, Inc. $52.48 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625335
Principal investigator 1 Alkermes, Inc. $56.85 04/03/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208625826
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $3,850.00 02/24/2025 Non-covered Recipient Entity
Pharmadev Clinical Research Institute Llc
BAY 3427080, A randomized, parallel-group treatment, Phase 2, double-blind pilot study to investigate the efficacy and safety of elinzanetant compared with placebo for treatment of sleep disturbances associated with menopause. No dispute reported 06/30/2026 1225404139
Principal investigator 1 LivaNova USA, Inc. $4,636.25 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245552629
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552710
Principal investigator 1 LivaNova USA, Inc. $337.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552713
Principal investigator 1 LivaNova USA, Inc. $1,351.25 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552718
Principal investigator 1 LivaNova USA, Inc. $2,002.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552722
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552726
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552867
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552871
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552873
Principal investigator 1 LivaNova USA, Inc. $33.75 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552878
Principal investigator 1 LivaNova USA, Inc. $337.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552882
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552886
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552889
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552893
Principal investigator 1 LivaNova USA, Inc. $67.50 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
OSPREY No dispute reported 06/30/2026 1245552897
Principal investigator 1 LivaNova USA, Inc. $4,636.25 02/15/2025 Non-covered Recipient Entity
SLEEP MEDICINE SPECIALISTS OF SOUTH FLORIDA
(OSPREY)Treating Obstructive Sleep APnea using TaRgetEd HYpoglossal Neurostimulation No dispute reported 06/30/2026 1245553023
Principal investigator 1 Alkermes, Inc. $17.10 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208613095
Principal investigator 1 Alkermes, Inc. $47.75 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208614174
Principal investigator 1 Alkermes, Inc. $412.40 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208617583
Principal investigator 1 Alkermes, Inc. $6.40 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208618233
Principal investigator 1 Alkermes, Inc. $162.05 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208619227
Principal investigator 1 Alkermes, Inc. $9.00 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620381
Principal investigator 1 Alkermes, Inc. $100.30 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208620626
Principal investigator 1 Alkermes, Inc. $89.95 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208623846
Principal investigator 1 Alkermes, Inc. $50.00 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626698
Principal investigator 1 Alkermes, Inc. $52.80 02/12/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208626714
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,072.25 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741694
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,072.25 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741696
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741698
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $9,389.79 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741700
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,072.25 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741702
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $12,237.75 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741704
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741706
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741708
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,628.10 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741710
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741712
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,072.25 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741714
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,115.10 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741716
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741718
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741720
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $602.10 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741722
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741724
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741726
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741728
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741730
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $602.10 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741732
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741734
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $13.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741736
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741738
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741740
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741742
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $2,072.25 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741744
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741746
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741748
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741750
Principal investigator 1 JAZZ PHARMACEUTICALS INC. $1,444.50 02/03/2025 Non-covered Recipient Entity
PharmaDev Clinical Research Institute, LLC
A Prospective, Open-Label, Single-Arm, Multicenter Study to Evaluate the Effect of Low-Sodium Oxybate Oral Solution (XYWAV) on Sleepiness, Polysomnography, and Functional Outcomes in Adult Participants Aged 18 to 75 Years With Idiopathic Hypersomnia or Narcolepsy No dispute reported 06/30/2026 1233741752
Principal investigator 1 Bayer Healthcare Pharmaceuticals Inc. $750.00 01/27/2025 Non-covered Recipient Entity
Pharmadev Clinical Research Institute Llc
BAY 3427080, A randomized, parallel-group treatment, Phase 2, double-blind pilot study to investigate the efficacy and safety of elinzanetant compared with placebo for treatment of sleep disturbances associated with menopause. No dispute reported 06/30/2026 1225407160
Principal investigator 1 Alkermes, Inc. $15,156.91 01/01/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 1 No dispute reported 06/30/2026 1208627092
Principal investigator 1 Alkermes, Inc. $10,678.47 01/01/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
A Phase 2, Parallel-Group, Dose-Range-Finding Study With Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects With Narcolepsy Type 2 No dispute reported 06/30/2026 1208627170
Principal investigator 1 Alkermes, Inc. $16,536.51 01/01/2025 Non-covered Recipient Entity
PHARMADEV CLINICAL RESEARCH INSTITUTE, LLC
An Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Durability of Treatment Effect of ALKS 2680 in Subjects With Narcolepsy Type 1 and Type 2 and Idiopathic Hypersomnia No dispute reported 06/30/2026 1208627240